Fig. 1

Cytokine expression profiles of skin-homing and splenic regulatory T cells (Tregs) in bleomycin (BLM)-treated mice and interleukin (IL)-33 expression in the lesional skin of BLM-treated mice. a Evaluation of skin-homing Tregs from BLM-treated wild-type (WT) and Fli1^+/− mice on IL-4, IL-13, IL17A, and IFN-γ expression by flow cytometry (n = 6). Gating strategy for identification of CD4⁺FoxP3⁺ Tregs is shown in the leftmost panel. b Evaluation of splenic Tregs from BLM-treated WT and Fli1^+/− mice on IL-4, IL-17A, and IFN-γ expression by flow cytometry (n = 6). c qRT-PCR evaluation of Il33 messenger RNA (mRNA) expression in the lesional skin of WT and Fli1^+/− mice treated with BLM for 1 week (n = 10). d Representative images of staining for IL-33 in skin samples from WT and Fli1^+/− mice treated with BLM for 1 week (original magnification ×400, scale bar = 50 μm). e The result of immunostaining without anti-IL-33 antibody in the skin of BLM-treated WT mice. Images of high-power field spotlighting dermal fibroblasts are in the rightmost column. Representative plots of one of five to eight individual animals from at least two separate experiments are shown in (a). In each graph, the relative value compared with the control group is expressed as mean ± SEM. AU Arbitrary units, Fli1 Friend leukemia virus integration 1, SSC-A Side scatter area